HA
XGN icon

Huntleigh Advisors’s Exagen XGN Stock Holding History

Huntleigh Advisors’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57,188
Closed -$348K – 307
2025
Q4 		$348K Sell
57,188
-36,165
-39% -$329K 0.06% 202
2025
Q3 		$1.03M Buy
93,353
+5,492
+6% +$48.6K 0.18% 116
2025
Q2 		$613K Buy
87,861
+4,753
+6% +$28.9K 0.12% 133
2025
Q1 		$298K Buy
83,108
+11,939
+17% +$45.1K 0.07% 188
2024
Q4 		$292K Buy
+71,169
New +$256K 0.06% 198

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Huntleigh Advisors's XGN Position: Q1 2026 in Review

Huntleigh Advisors sold out of Exagen (XGN) in Q1 2026, closing a stake of 57,188 shares — an estimated $348K sold.

Huntleigh Advisors first reported a position in XGN in Q4 2024 and held it in 5 quarters. The position peaked at $1.03M in Q3 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Huntleigh Advisors reported no remaining Exagen position as of Q1 2026 after selling out during the quarter.
  • Huntleigh Advisors sold 57,188 Exagen shares in Q1 2026, an estimated $348K.
  • Huntleigh Advisors first reported a position in Exagen in Q4 2024 and held it in 5 quarters.
  • Huntleigh Advisors's Exagen position peaked at $1.03M in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Huntleigh Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.